Global antibiotics market: Antibiotic-resistant bacteria is one of the top global risks
2004, a report published by the Infectious Diseases Society of America (IDSA) warned that "infections that were once easily curable with antibiotics are becoming difficult, even impossible, to treat, and an increasing number of people are suffering severe illness - or dying - as a result."
There is currently a gap between multidrug-resistant bacteria and the development of new antibacterial agents. This gap is particularly significant, given that antibiotic research and development is characterised by long lead times. In this context, public health experts are expressing concerns regarding a possible return to the pre-biotic era. The recent Global Risks Report, published by the World Economic Forum, describes antibiotic-resistant bacteria as an existential threat and one of the top 50 global risks faced by humanity today.
1111111111111111
The discovery of the first antibiotic nearly a century ago revolutionized the global healthcare industry, reducing the incidence of the morbidity and mortality due to dangerous infectious diseases. The global antibiotics market is estimated to have been $39.6 billion in 2013 and is expected to reach $41.2 billion in 2018. The global aging population and the increased prevalence of hospital-acquired infections are the primary factors driving the growth of the antibiotics market. Economic conditions and cost-containment issues have compelled North American and European antibiotic manufacturers to explore new regions, such as India, China and Brazil, for growth opportunities.
There has been a paradigm shift in the regulatory framework, causing a positive impact on the overall growth of the antibiotics market; however, the economic slowdown and the patent expiry of major antibiotics during the forecast period will limit the growth of the market. In order to keep abreast of this change, antibiotic manufacturers are using various novel technologies to reduce antibiotic resistance in order to yield novel antibiotics.
It is expected that this trend will continue with the aim of solving the current challenges and fulfilling the unmet needs of the market. North America accounted for the largest market in 2013 followed by Europe. However, Asian countries represent the fastest-growing markets due to the increasing aging population, increasing GDP rate and increasing awareness about healthcare.
The leading players in the global antibiotics market include Pfizer Inc. (U.S.), Merck and Co. (U.S.), Eli Lilly and Co. (U.S.), Sanofi-Aventis (France), AstraZeneca (U.K.), Cubist pharmaceuticals (U.S.), Johnson & Johnson (U.S.) and GlaxoSmithKline PLC (U.K.).
1111111111111111
The discovery of the first antibiotic nearly a century ago revolutionized the global healthcare industry, reducing the incidence of the morbidity and mortality due to dangerous infectious diseases. The global antibiotics market is estimated to have been $39.6 billion in 2013 and is expected to reach $41.2 billion in 2018. The global aging population and the increased prevalence of hospital-acquired infections are the primary factors driving the growth of the antibiotics market. Economic conditions and cost-containment issues have compelled North American and European antibiotic manufacturers to explore new regions, such as India, China and Brazil, for growth opportunities.
There has been a paradigm shift in the regulatory framework, causing a positive impact on the overall growth of the antibiotics market; however, the economic slowdown and the patent expiry of major antibiotics during the forecast period will limit the growth of the market. In order to keep abreast of this change, antibiotic manufacturers are using various novel technologies to reduce antibiotic resistance in order to yield novel antibiotics.
It is expected that this trend will continue with the aim of solving the current challenges and fulfilling the unmet needs of the market. North America accounted for the largest market in 2013 followed by Europe. However, Asian countries represent the fastest-growing markets due to the increasing aging population, increasing GDP rate and increasing awareness about healthcare.
The leading players in the global antibiotics market include Pfizer Inc. (U.S.), Merck and Co. (U.S.), Eli Lilly and Co. (U.S.), Sanofi-Aventis (France), AstraZeneca (U.K.), Cubist pharmaceuticals (U.S.), Johnson & Johnson (U.S.) and GlaxoSmithKline PLC (U.K.).
No comments:
Post a Comment